In this article, the authors discuss new approaches to treating iron overload diseases using hepcidin mimetics or by modulating endogenous hepcidin expression. In particular, the authors discuss lipid nanoparticle encapsulated siRNA and antisense oligonucleotide-mediated inhibition of TMPRSS6, an upstream regulator of hepcidin, and treatment with transferrin or hepcidin mimetics, including the recently described minihepcidins. In each case, in animal models of β-thalassemia, not only do the interventions affect iron absorption but they also act as disease-modifying agents that ameliorate the ineffective erythropoiesis.
Keywords: Hepcidin/minihepcidins; Hereditary hemochromatosis; Ineffective erythropoiesis; Iron metabolism; Lipid nanoparticle siRNA/antisense oligonucleotide; β-Thalassemia.
Copyright © 2014 Elsevier Inc. All rights reserved.